Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Equivir - GRDG Sciences

Drug Profile

Equivir - GRDG Sciences

Latest Information Update: 06 Mar 2020

At a glance

  • Originator GRDG Sciences
  • Class Antivirals; Flavonoids; Phenols
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical COVID 2019 infections; Dengue; Ebola virus infections; Influenza A virus H1N1 subtype; Influenza A virus H3N2 subtype; Influenza A virus H5N1 subtype; Influenza A virus H7N9 subtype; Influenza B virus infections; Parainfluenza virus infections; Rhinovirus infections

Most Recent Events

  • 25 Feb 2020 Global Biolife has multiple patents pending for phenolic compounds in multiple countries before February 2020
  • 25 Feb 2020 Preclinical trials in COVID-2019-infections in USA (unspecified route) before February 2020
  • 25 Feb 2020 Preclinical trials in Dengue in USA (unspecified route) before February 2020

Development Overview

Introduction

Equivir is a combination of myricetin, hesperidin and piperine phenolic flavonoid compounds, being developed by GRDG Sciences for the treatment of various viral infections including influenza (H1N1, H3N2, H5N1, H7N9, Influenza B, Parainfluenza 3), rhinovirus, ebola, dengue virus and coronavirus infection (COVID-2019-infections and Human Coronavirus-A). In preclinical studies, equivir showed enhanced antiviral properties in terms of efficacy in treating influenza, dengue virus and ebola. Preclinical development is underway in the US.

Key Development Milestones

As of February 2020, Equivir demonstrated in vitro efficacy against multiple strains of Influenza (H1N1, H3N2, H5N1, H7N9, Influenza B, Parainfluenza 3), Human Rhinovirus-14, Human Coronavirus-A, and Ebola. The company intends to conduct additional testing for the equivir for the treatment of COVID-2019 infections, the disease caused by the pandemic novel coronavirus SARS-CoV2 [1] .

Patent Information

As of February 2020, Global Biolife has a multiple patents pending worldwide for electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders [2]

In November 2018, Global Biolife has patent US 10 123 991 B2 granted for electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders in the US. The patent will expire in May 2036 [2] .

Drug Properties & Chemical Synopsis

  • Formulation unspecified
  • Class Antivirals, Flavonoids, Phenols
  • Mechanism of Action Undefined mechanism
  • WHO ATC code

    J05 (Antivirals for Systemic Use)

  • EPhMRA code

    J5 (Antivirals for Systemic Use)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - - Preclinical USA unspecified / unspecified GRDG Sciences 25 Feb 2020
Dengue - - Preclinical USA unspecified / unspecified GRDG Sciences 25 Feb 2020
Ebola virus infections - - Preclinical USA unspecified / unspecified GRDG Sciences 25 Feb 2020
Influenza A virus H1N1 subtype - - Preclinical USA unspecified / unspecified GRDG Sciences 25 Feb 2020
Influenza A virus H3N2 subtype - - Preclinical USA unspecified / unspecified GRDG Sciences 25 Feb 2020
Influenza A virus H5N1 subtype - - Preclinical USA unspecified / unspecified GRDG Sciences 25 Feb 2020
Influenza A virus H7N9 subtype - - Preclinical USA unspecified / unspecified GRDG Sciences 25 Feb 2020
Influenza B virus infections - - Preclinical USA unspecified / unspecified GRDG Sciences 25 Feb 2020
Parainfluenza virus infections - - Preclinical USA unspecified / unspecified GRDG Sciences 25 Feb 2020
Rhinovirus infections - - Preclinical USA unspecified / unspecified GRDG Sciences 25 Feb 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
GRDG Sciences Originator USA
GRDG Sciences Owner USA
Global BioLife. Collaborator USA

Development History

Event Date Update Type Comment
25 Feb 2020 Patent Information Global Biolife has multiple patents pending for phenolic compounds in multiple countries before February 2020 [2] Updated 06 Mar 2020
25 Feb 2020 Phase Change - Preclinical Preclinical trials in COVID-2019-infections in USA (unspecified route) before February 2020 [1] Updated 06 Mar 2020
25 Feb 2020 Phase Change - Preclinical Preclinical trials in Dengue in USA (unspecified route) before February 2020 [1] Updated 06 Mar 2020
25 Feb 2020 Phase Change - Preclinical Preclinical trials in Ebola virus infections in USA (unspecified route) before February 2020 [1] Updated 06 Mar 2020
25 Feb 2020 Phase Change - Preclinical Preclinical trials in Influenza A virus H1N1 subtype in USA (unspecified route) before February 2020 [1] Updated 06 Mar 2020
25 Feb 2020 Phase Change - Preclinical Preclinical trials in Influenza A virus H3N2 subtype in USA (unspecified route) before February 2020 [1] Updated 06 Mar 2020
25 Feb 2020 Phase Change - Preclinical Preclinical trials in Influenza A virus H5N1 subtype in USA (unspecified route) before February 2020 [1] Updated 06 Mar 2020
25 Feb 2020 Phase Change - Preclinical Preclinical trials in Influenza A virus H7N9 subtype in USA (unspecified route) before February 2020 [1] Updated 06 Mar 2020
25 Feb 2020 Phase Change - Preclinical Preclinical trials in Influenza B virus infections in USA (unspecified route) before February 2020 [1] Updated 06 Mar 2020
25 Feb 2020 Phase Change - Preclinical Preclinical trials in Parainfluenza virus infections in USA (unspecified route) before February 2020 [1] Updated 06 Mar 2020
25 Feb 2020 Phase Change - Preclinical Preclinical trials in Rhinovirus infections in USA (unspecified route) before February 2020 [1] Updated 06 Mar 2020
13 Nov 2018 Patent Information Global Biolife has patent protection for phenolic compounds in USA [2] Updated 06 Mar 2020

References

  1. GRDG Sciences Announces Successful Antiviral Testing of Equivir Preparations Underway for Coronavirus Testing.

    Media Release
  2. Global Biolife INC-Patent. Internet-Doc 2020;.

    Available from: URL: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017201042
Back to top